Internet Based Cognitive Behavioral Therapy Effects on Depressive Cognitions and Brain Function (iCBT)

May 3, 2021 updated by: Scott Rauch, Mclean Hospital
The purpose of this study is to understand the effectiveness of a ten-week internet-based cognitive behavioral therapy (iCBT) treatment on improving depressive symptoms, coping and resilience skills, and cognitive processing.

Study Overview

Status

Completed

Detailed Description

The need for mental health services is high among military personnel but perceived stigma and other barriers prevent many Soldiers from obtaining the help they need. Alternative mental health treatment approaches that mitigate stigma and increase access and compliance are greatly needed. One promising treatment approach that has shown efficacy in preliminary research and which may address issues related to stigma and barriers to care, is internet-based cognitive behavioral therapy (iCBT). Internet-based treatments offer brief, interactive, and structured treatment approaches that can be completed by individuals relatively anonymously, in the convenience and privacy of their own homes, and according to their own schedules. Such interventions could offer Soldiers an alternative treatment method that minimizes stigma by allowing private and quasi-anonymous access to treatment and which minimizes barriers to care by enhancing access and maximizing schedule flexibility.

Emerging evidence suggests that iCBT is a particularly promising and well-accepted approach for treating large numbers of individuals while minimizing cost and clinicians' time demand. The study of internet-based and other computer-assisted therapies is currently in its infancy and most studies still lack sufficient methodological rigor to firmly establish the efficacy and applicability of these approaches. The proposed project will provide the most comprehensive evaluation of iCBT to date by employing functional neuroimaging techniques, neurocognitive testing of implicit negative biases and responses to negative feedback, and assessment of resilience and coping capacities in addition to standard symptom-based outcome measures.

Study Type

Interventional

Enrollment (Actual)

77

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Massachusetts
      • Belmont, Massachusetts, United States, 02478
        • Isabelle Rosso

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion criteria:

  • Age range between 18 and 45.
  • Subjects must be right handed (as measured by Edinburgh Handedness Inventory).
  • The primary language of the subjects must be English
  • Must have regular access to a computer with internet connection and printer (for potential MDD or MAC participants)
  • DSM-IV criteria for current Major Depressive Episode according to SCID (for enrollment into MDD or MAC groups)
  • Absence of any psychotropic medications for at least 2 weeks (6 weeks for fluoxetine; 6 months for neuroleptics; 2 weeks for benzodiazepines; 2 weeks for any other antidepressants)
  • PHQ-9 score below 5 (for enrollment into HC group)

Exclusion criteria:

  • Any history of neurological illness or brain injury
  • Current or past DSM-IV Axis I disorder (for enrollment into HC group)
  • Complicating medical conditions that may influence the outcome of neuropsychological assessment or functional imaging (e.g., HIV)
  • Mixed or left-handedness
  • Abnormal visual acuity that is not corrected by contact lenses
  • Metal within the body, claustrophobia, or other contraindications for MRI
  • Less than 9th grade education
  • Past or current alcohol/substance dependence, or current alcohol abuse, or current or past substance abuse (i.e. past alcohol abuse is not exclusionary)
  • Use of illicit drugs within the past year
  • Use of marijuana within the past month
  • Current use of opioid or prescribed stimulant medications
  • History of a psychotic mental illness (schizophrenia or bipolar disorder)
  • Current severe symptoms of depression (total score > 23 or responding > 1 to Question 9 for suicidal ideation in the Patient Health Questionnaire-9 Item [PHQ-9] (Kroenke et al., 2001))
  • A PHQ-9 score below 10 (for potential MDD or MAC participants)
  • Currently participating in Cognitive Behavior Therapy
  • History of ECT treatment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Internet Cognitive Behavioral Therapy
Participants with major depressive disorder receive an 8-week long internet-based cognitive behavioral therapy program.
8 weeks of online treatment program
No Intervention: Monitored Attention Control
Participants with major depressive disorder receive no treatment but are monitored closely for 8 weeks. Participants in this arm are offered the treatment at the end of the study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change From Pre-treatment to Post-treatment (10 Weeks), Measured by the Hamilton Rating Scale for Depression, 17 Item Version (HRSD-17).
Time Frame: Measured at the baseline visit and 10 weeks after the baseline visit
To assess change in severity of depression symptoms. The total score is reported, which is the sum of the ratings of all items and ranges from 0 to 52, with higher scores indicating a worse outcome or greater severity of depression symptoms.
Measured at the baseline visit and 10 weeks after the baseline visit

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Weekly Patient Health Questionnaire (PHQ-9) Score
Time Frame: Baseline visit, and 10 weeks after baseline visit
Participants' scores on the PHQ-9 will be measured at baseline before treatment, each week during the treatment, and again at 10 weeks post-treatment. The range of possible scores on the PHQ-9 is 0 to 27 and higher scores indicate worse outcome or more severe depression
Baseline visit, and 10 weeks after baseline visit
Weekly Kessler Psychological Distress Scale (K-10) Score
Time Frame: Week 10 score
The K-10 is a 10-item self-report measure of psychological distress. Items are scored on a scale from 1" ("none of the time") to "5" ("all of the time"). Total K-10 scores range from 10 to 50, with higher scores reflecting worse outcome or higher distress.
Week 10 score
Improvement From Baseline in Brain Functioning on the Emotional Interference Task (EIT) and the Monetary Incentive Delay Task (MID)
Time Frame: baseline, 10 weeks
At 10 weeks (post-treatment), we will look for improvement from baseline in key brain regions known to be affected by depression. Differences in EIT and MID task-related brain responses will be measured.
baseline, 10 weeks
Change From Baseline in Positive and Negative Affect Scale (PANAS) Score
Time Frame: Baseline visit and 10 weeks after baseline visit
Participants' scores on the PANAS will be measured at baseline before treatment, and again at 10 weeks post-treatment. Two scores can be derived. 1) A positive affect score can range from 10 to 50, with higher scores representing better outcome or higher levels of positive affect; 2) Negative Affect score can range from 10 to 50, with higher scores representing better outcome or lower levels of negative affect.
Baseline visit and 10 weeks after baseline visit
Change From Baseline in Connor Davidson Resilience Scale (CD-RISC) Score
Time Frame: Baseline visit, and 10 weeks after baseline visit
Participants' scores on the CD-RISC will be measured at baseline before treatment, and again at 10 weeks post-treatment. Total scores range from 0 to 100, with higher scores indicating a better outcome or higher resilience
Baseline visit, and 10 weeks after baseline visit
Change From Baseline in Modified Erikson Flanker Test
Time Frame: Baseline visit and 10 weeks after baseline visit.
Participants' scores on the Modified Erikson Flanker Test will be measured at baseline before treatment, and again at 10 weeks post-treatment. Accuracy scores range from 0 to 1 with higher scores reflecting better outcome.
Baseline visit and 10 weeks after baseline visit.
Change From Baseline in Implicit Association Test (IAT)
Time Frame: Baseline visit, 10 weeks after baseline visit.
Participants' scores on the IAT will be measured at baseline before treatment, and again at 10 weeks post-treatment. The IAT effect is called the D score with a possible range of -2 to +2, with larger scores reflecting worse outcome and stronger suicidality
Baseline visit, 10 weeks after baseline visit.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Scott L Rauch, MD, McLean Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2012

Primary Completion (Actual)

August 1, 2015

Study Completion (Actual)

August 1, 2015

Study Registration Dates

First Submitted

May 11, 2012

First Submitted That Met QC Criteria

May 11, 2012

First Posted (Estimate)

May 15, 2012

Study Record Updates

Last Update Posted (Actual)

May 25, 2021

Last Update Submitted That Met QC Criteria

May 3, 2021

Last Verified

May 1, 2021

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Major Depressive Disorder

Clinical Trials on Internet Cognitive Behavioral Therapy

Subscribe